Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) overview

Chronic inflammatory demyelinating polyneuropathy (CIDP), also called as chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal; orthostatic dizziness; and tingling and numbness of hands and feet.

For a complete picture of PTSR and LoA scores for drugs in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.